JSF Financial LLC Invests $894,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

JSF Financial LLC purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 9,993 shares of the medical equipment provider’s stock, valued at approximately $894,000.

A number of other large investors also recently modified their holdings of the business. Peterson Wealth Services lifted its holdings in shares of Lantheus by 4.9% during the fourth quarter. Peterson Wealth Services now owns 12,746 shares of the medical equipment provider’s stock worth $1,140,000 after buying an additional 596 shares during the last quarter. Focus Financial Network Inc. acquired a new position in shares of Lantheus during the fourth quarter worth approximately $292,000. Washburn Capital Management Inc. acquired a new position in shares of Lantheus during the fourth quarter worth approximately $206,000. Empowered Funds LLC acquired a new position in shares of Lantheus during the fourth quarter worth approximately $8,210,000. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Lantheus by 32.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 8,764 shares of the medical equipment provider’s stock valued at $784,000 after purchasing an additional 2,127 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of LNTH stock opened at $86.91 on Tuesday. The stock’s fifty day moving average is $92.02 and its 200-day moving average is $98.46. The stock has a market capitalization of $6.04 billion, a PE ratio of 14.46 and a beta of 0.44. Lantheus Holdings, Inc. has a 52 week low of $54.69 and a 52 week high of $126.89.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LNTH. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. JMP Securities restated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial restated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.